{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T19:23:12Z","timestamp":1771701792218,"version":"3.50.1"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2022-0118_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The four-tied peritoneal regression grading score (PRGS) is increasingly used to evaluate the response of\u00a0peritoneal metastases (PM) to chemotherapy. The minimal number of peritoneal biopsies needed for PRGS determination remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0118_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort of 89 PM patients treated with 210 pressurized intraperitoneal aerosol chemotherapy (PIPAC) cycles was investigated. Four biopsies from every abdominal quadrant were recommended. Histological tumor response was defined as a stable or decreasing mean PRGS between therapy cycles, progression increasing. We compared the diagnostic uncertainty induced by missing biopsies to the histological response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0118_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 49 patients had at least two PIPAC and were eligible for therapy response assessment. Mean PRGS decreased from 2.04 (CI 5\u201395% 1.85\u20132.27) to 1.79 (CI 5\u201395% 1.59\u20132.01), p=0.14, as a proof of therapy effectiveness. 35\u00a0(71.4%) patients had a stable or decreasing PRGS (therapy response), 14 (28.6%) a PRGS increase (disease progression). Histology showed agreement between four biopsies in 42\/210 laparoscopies (20%), between\u00a0\u22653 biopsies in 103 (49%), and between\u00a0\u22652 biopsies in 169 laparoscopies (81%). Mean loss of information with one missing biopsy was 0.11 (95% CI=0.13) PRGS points, with two missing biopsies 0.18 (95% CI 0.21). In 9\/49 patients (18.3%), the loss of information with one less biopsy exceeded the change in PRGS under therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0118_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A minimum of three biopsies is needed to\u00a0diagnose PM progression with an accuracy superior to 80%. Missing biopsies often result in a false diagnosis of tumor progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2022-0118","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:41:28Z","timestamp":1663980088000},"page":"179-185","source":"Crossref","is-referenced-by-count":5,"title":["Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined?"],"prefix":"10.1515","volume":"7","author":[{"given":"Wiebke","family":"Solass","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Bern , Bern , Switzerland"},{"name":"National Center for Pleura and Peritoneum , Tuebingen , Germany"},{"name":"Institute of Pathology, Eberhard-Karls-University Tuebingen , Tuebingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Meisner","sequence":"additional","affiliation":[{"name":"Institute for Clinical Epidemiology and Applied Biometry, Eberhard-Karls-University Tuebingen , Tuebingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Deptartment of General and Transplant Surgery, Eberhard-Karls-University Tuebingen , Tuebingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgi","family":"Nadiradze","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum , Tuebingen , Germany"},{"name":"Deptartment of General and Transplant Surgery, Eberhard-Karls-University Tuebingen , Tuebingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Reymond","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum , Tuebingen , Germany"},{"name":"Deptartment of General and Transplant Surgery, Eberhard-Karls-University Tuebingen , Tuebingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"B\u00f6sm\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Bern , Bern , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"2025120909231608861_j_pp-2022-0118_ref_001","doi-asserted-by":"crossref","unstructured":"Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"2025120909231608861_j_pp-2022-0118_ref_002","doi-asserted-by":"crossref","unstructured":"Lambert, LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 2015;65:284\u201398. https:\/\/doi.org\/10.3322\/caac.21277.","DOI":"10.3322\/caac.21277"},{"key":"2025120909231608861_j_pp-2022-0118_ref_003","doi-asserted-by":"crossref","unstructured":"Huang, Z, Liu, D, Chen, X, Yu, P, Wu, J, Song, B, et al.. Retrospective imaging studies of gastric cancer: study protocol clinical trial (SPIRIT Compliant). Medicine (Baltim) 2020;99:e19157. https:\/\/doi.org\/10.1097\/md.0000000000019157.","DOI":"10.1097\/MD.0000000000019157"},{"key":"2025120909231608861_j_pp-2022-0118_ref_004","doi-asserted-by":"crossref","unstructured":"Dong, D, Tang, L, Li, ZY, Fang, MJ, Gao, JB, Shan, XH, et al.. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol 2019;30:431\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz001.","DOI":"10.1093\/annonc\/mdz001"},{"key":"2025120909231608861_j_pp-2022-0118_ref_005","doi-asserted-by":"crossref","unstructured":"Enomoto, LM, Levine, EA, Perry, KC, Votanopoulos, KI, Kuncewitch, M, Shen, P. Minimally invasive surgical approaches for peritoneal surface malignancy. Surg Oncol Clin 2019;28:161\u201376. https:\/\/doi.org\/10.1016\/j.soc.2018.11.010.","DOI":"10.1016\/j.soc.2018.11.010"},{"key":"2025120909231608861_j_pp-2022-0118_ref_006","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909231608861_j_pp-2022-0118_ref_008","doi-asserted-by":"crossref","unstructured":"Bakrin, N, Tempfer, C, Scambia, G, De Simone, M, Gabriel, B, Grischke, EM, et al.. PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Pleura Peritoneum 2018;3:20180114. https:\/\/doi.org\/10.1515\/pp-2018-0114.","DOI":"10.1515\/pp-2018-0114"},{"key":"2025120909231608861_j_pp-2022-0118_ref_009","doi-asserted-by":"crossref","unstructured":"Elleb\u00e6k, SB, Graversen, M, Detlefsen, S, Lundell, L, Fristrup, CW, Pfeiffer, P, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis 2020;37:325\u201332. https:\/\/doi.org\/10.1007\/s10585-020-10023-5. PMID: 32002724.","DOI":"10.1007\/s10585-020-10023-5"},{"key":"2025120909231608861_j_pp-2022-0118_ref_010","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Pfeiffer, P, Lundell, L, Mortensen, MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 2018;35:103\u20138. https:\/\/doi.org\/10.1007\/s10585-018-9895-9.","DOI":"10.1007\/s10585-018-9895-9"},{"key":"2025120909231608861_j_pp-2022-0118_ref_011","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Ellebaek, SB, Fristrup, C, Pfeiffer, P, Mortensen, MB. Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. Eur J Surg Oncol 2020;46:155\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2019.08.024.","DOI":"10.1016\/j.ejso.2019.08.024"},{"key":"2025120909231608861_j_pp-2022-0118_ref_012","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Asmussen, J, Mahdi, B, Fristrup, C, Pfeiffer, P, et al.. Treatment of peritoneal carcinomatosis with pressurized IntraPeritoneal aerosol chemotherapy - PIPAC-OPC2. Pleura Peritoneum 2018;3:20180108. https:\/\/doi.org\/10.1515\/pp-2018-0108.","DOI":"10.1515\/pp-2018-0108"},{"key":"2025120909231608861_j_pp-2022-0118_ref_013","doi-asserted-by":"crossref","unstructured":"Horvath, P, Yurttas, C, Struller, F, B\u00f6sm\u00fcller, H, Lauer, UM, Nadalin, S, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases in solid organ graft recipients: first experience. Ann Transplant 2019;24:30\u20135. https:\/\/doi.org\/10.12659\/aot.911905.","DOI":"10.12659\/AOT.911905"},{"key":"2025120909231608861_j_pp-2022-0118_ref_014","doi-asserted-by":"crossref","unstructured":"Kurtz, F, Struller, F, Horvath, P, Solass, W, B\u00f6sm\u00fcller, H, K\u00f6nigsrainer, A, et al.. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract 2018;2018:2743985. https:\/\/doi.org\/10.1155\/2018\/2743985.","DOI":"10.1155\/2018\/2743985"},{"key":"2025120909231608861_j_pp-2022-0118_ref_015","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Bjerregaard, JK, Fristrup, CW, Pfeiffer, P, Mortensen, MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1758835918777036. https:\/\/doi.org\/10.1177\/1758835918777036.","DOI":"10.1177\/1758835918777036"},{"key":"2025120909231608861_j_pp-2022-0118_ref_016","doi-asserted-by":"crossref","unstructured":"Benzerdjeb, N, Durieux, E, Tantot, J, Isaac, S, Fontaine, J, Harou, O, et al.. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology 2020;77:548\u201359. https:\/\/doi.org\/10.1111\/his.14092. PMID: 32060943.","DOI":"10.1111\/his.14092"},{"key":"2025120909231608861_j_pp-2022-0118_ref_017","doi-asserted-by":"crossref","unstructured":"Schwartz, LH, Liti\u00e8re, S, de Vries, E, Ford, R, Gwyther, S, Mandrekar, S, et al.. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2025120909231608861_j_pp-2022-0118_ref_007","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Carr, NJ, Bibeau, F, Neureiter, D, J\u00e4ger, T, et al.. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology 2019;74:1014\u201324. https:\/\/doi.org\/10.1111\/his.13829.","DOI":"10.1111\/his.13829"},{"key":"2025120909231608861_j_pp-2022-0118_ref_018","doi-asserted-by":"crossref","unstructured":"Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025120909231608861_j_pp-2022-0118_ref_019","doi-asserted-by":"crossref","unstructured":"Chetty, R, Gill, P, Govender, D, Bateman, A, Chang, HJ, Deshpande, V, et al.. A. Bateman International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol 2012;43:1917\u201323. https:\/\/doi.org\/10.1016\/j.humpath.2012.01.020.","DOI":"10.1016\/j.humpath.2012.01.020"},{"key":"2025120909231608861_j_pp-2022-0118_ref_020","doi-asserted-by":"crossref","unstructured":"Dagogo-Jack, I, Shaw, AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018;15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166.","DOI":"10.1038\/nrclinonc.2017.166"},{"key":"2025120909231608861_j_pp-2022-0118_ref_021","doi-asserted-by":"crossref","unstructured":"Yuan, S, Norgard, RJ, Stanger, BZ. Cellular plasticity in cancer. Cancer Discov 2019;9:837\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0015.","DOI":"10.1158\/2159-8290.CD-19-0015"},{"key":"2025120909231608861_j_pp-2022-0118_ref_022","doi-asserted-by":"crossref","unstructured":"Kaye, P, Lindsay, D, Madhusudan, S, Vohra, R, Catton, J, Platt, C, et al.. Upper GI biopsies for adenocarcinoma \u2013 how many biopsies should endoscopists take? Histopathology 2019;74:959\u201363. https:\/\/doi.org\/10.1111\/his.13816. PMID: 30592780.","DOI":"10.1111\/his.13816"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0118\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:59:21Z","timestamp":1765277961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0118\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2022,12,13]]}},"alternative-id":["10.1515\/pp-2022-0118"],"URL":"https:\/\/doi.org\/10.1515\/pp-2022-0118","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}